Company Insights

STVN supplier relationships

Explore interactive graphBrowse insights index
STVN supplier relationship map

Stevanato Group (STVN): The supplier relationships that drive capital and operations

Stevanato Group builds and sells advanced drug containment and delivery components—glass and polymer primary packaging, integrated systems, and assembly services—to pharmaceutical and biotech customers, and it monetizes through high-volume manufacturing contracts, equipment sales and recurring service agreements. Capital markets relationships and strategic manufacturing partners are part of the company’s operating backbone: banks and underwriters provide financing and liquidity while industrial partners supply fill‑and‑finish or assembly capability that completes Stevanato’s customer offering.

If you evaluate supplier and counterparty risk for STVN, start with how financing and strategic-tier partners reduce cash volatility and accelerate go‑to‑market execution. For a quick view of portfolio exposure and relationship concentration, visit Null Exposure: https://nullexposure.com/.

Business profile in plain terms

  • Stevanato’s revenue base is driven by long-cycle manufacturing contracts and recurring consumables sales; 2025 revenue was roughly €1.186 billion (RevenueTTM $1,186,282,000 in the company overview), with healthy gross and operating margins. The firm’s business model combines manufacturing scale with capital intensity, so access to committed financing and top-tier underwriters is a continuing operational necessity.
  • Capital relationships reduce balance-sheet risk, while operational partners (e.g., fill-and-finish providers) control time-to-market for large-volume systems. This structure makes financing counterparties and industrial partners functionally equivalent to suppliers in an operational-risk sense.

Read more company-level context on Null Exposure: https://nullexposure.com/.

How to think about Stevanato’s supplier posture

  • Contracting posture: The company uses syndicated financing and public offerings with multiple lead managers, reflecting a preference for diversified capital partners rather than concentrated bilateral lending.
  • Concentration: Financing and underwriting relationships are concentrated among top-tier global banks and a select industrial partner for final assembly; supplier concentration exists but is diversified across multiple financial and capital partners.
  • Criticality: Banks and underwriters are critical for liquidity and capital raises; industrial partners that provide fill-and-finish services are critical for delivering complete customer solutions.
  • Maturity: Engagements with established global banks and longstanding industrial partners point to mature, institutional relationships rather than ad-hoc suppliers.

Mid‑report action: if you require a mapped counterparty exposure report for STVN, request it at Null Exposure: https://nullexposure.com/.

Detailed relationship list (each entry from the company’s IR results)

  • Cassa Depositi e Prestiti — Stevanato announced a €200 million financing package in FY2025 that included Cassa Depositi e Prestiti as a lender in the syndicate, demonstrating Italian public‑sector bank involvement in the company’s capital structure. Source: Stevanato IR press release (detail/165), FY2025, first seen 2026-03-10.
  • Citigroup — Citigroup acted as a joint book-running manager on Stevanato’s upsized public offering in FY2024, reflecting its role in underwriting and distribution for equity capital raises. Source: Stevanato IR press release (detail/139), FY2024, first seen 2026-03-10.
  • Citigroup (duplicate entry) — The company’s filings repeat Citigroup’s participation as a book‑running manager for FY2024 capital markets activity. Source: Stevanato IR press release (detail/140), FY2024, first seen 2026-03-10.
  • Morgan Stanley & Co. LLC — Morgan Stanley served as a lead book-running manager and representative of the underwriters for the FY2024 offering, indicating a primary underwriting role in Stevanato’s public placement. Source: Stevanato IR press release (detail/140), FY2024, first seen 2026-03-10.
  • Thermo Fisher Scientific — Thermo Fisher will provide fill‑and‑finish and final assembly services for Stevanato’s large-volume Vertiva product, making Thermo Fisher an operational partner essential to completing finished drug delivery systems. Source: Stevanato IR press release (detail/153), FY2024, first seen 2026-03-10.
  • Banco BPM — Banco BPM joined the €200 million FY2025 financing package, placing a domestic Italian commercial bank within Stevanato’s syndicate lenders. Source: Stevanato IR press release (detail/165), FY2025, first seen 2026-03-10.
  • BNL BNP Paribas — BNL BNP Paribas is included in the FY2025 €200 million financing, adding an international commercial-bank footprint to the financing group. Source: Stevanato IR press release (detail/165), FY2025, first seen 2026-03-10.
  • BofA Securities — BofA Securities served as one of the joint book-running managers on the FY2024 upsized public offering, participating in underwriting and capital distribution. Source: Stevanato IR press release (detail/139), FY2024, first seen 2026-03-10.
  • Morgan Stanley (duplicate entry) — Morgan Stanley is listed again in FY2024 materials as a lead book-runner and underwriter representative for the offering. Source: Stevanato IR press release (detail/139), FY2024, first seen 2026-03-10.
  • KeyBanc Capital Markets — KeyBanc participated as a joint book-running manager in the FY2024 offering, contributing to the syndicate of equity underwriters. Source: Stevanato IR press release (detail/139), FY2024, first seen 2026-03-10.
  • Morgan Stanley (additional listing) — An additional FY2024 entry reiterates Morgan Stanley’s lead book‑running role and representative status for the underwriters. Source: Stevanato IR press release (detail/139), FY2024, first seen 2026-03-10.
  • William Blair & Company, L.L.C. — William Blair served alongside Morgan Stanley as a joint book‑running manager and representative of the underwriters for FY2024 offerings, positioning it within the distribution and underwriting team. Source: Stevanato IR press release (detail/138), FY2024, first seen 2026-03-10.
  • BofA Securities (duplicate entry) — BofA is reiterated in the FY2024 closing announcement as a joint book‑running manager, confirming its participation across both pricing and closing communications. Source: Stevanato IR press release (detail/140), FY2024, first seen 2026-03-10.
  • KeyBanc Capital Markets (duplicate entry) — KeyBanc’s participation is repeated in the FY2024 closing announcement as part of the underwriting syndicate. Source: Stevanato IR press release (detail/140), FY2024, first seen 2026-03-10.
  • William Blair (duplicate entry) — William Blair’s role is restated in closing communications that confirm the underwriting syndicate’s composition. Source: Stevanato IR press release (detail/139), FY2024, first seen 2026-03-10.
  • William Blair & Company, L.L.C. (additional listing) — The materials include multiple entries naming William Blair in its underwriting and distribution role for FY2024. Source: Stevanato IR press release (detail/140), FY2024, first seen 2026-03-10.

Constraints and what’s not in the feed

  • There are no explicit constraint excerpts captured in the supplier relationship feed; this is a company-level signal indicating the data pull included active relationship annotations but no regulatory or contractual constraint text. Use this as a reminder to request contractual schedules and covenant language directly from filings before concluding on lender covenants or supplier SLA exposure.

Investment and operational takeaways

  • Capital access is diversified across major global and Italian banks, reducing single-lender concentration risk for short- and medium-term funding.
  • Thermo Fisher’s involvement converts a product capability into a delivered solution, elevating operational criticality for that partner relative to pure financial counterparties.
  • Underwriter diversity (Morgan Stanley, Citigroup, BofA, KeyBanc, William Blair) signals institutional demand and a conventional public-equity capital strategy that supports liquidity and secondary markets.

Final call-to-action: if you need a tailored counterparty risk brief or a consolidated supplier map for STVN, get a custom report at Null Exposure: https://nullexposure.com/.

The firm’s financials—modest EPS, low beta and a forward P/E roughly 19.5—support a disciplined growth story where supplier selection and capital partners are core operational levers. For investor due diligence focused on supplier concentration, contract terms and real-world delivery partners, use Null Exposure to translate these relationship signals into actionable exposure analytics: https://nullexposure.com/.